NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00788892,Trial of CPX-351 in Newly Diagnosed Elderly AML Patients,https://clinicaltrials.gov/study/NCT00788892,,COMPLETED,"The study investigates if CPX-351 will be a) more effective than the standard AML treatment and b) more tolerable than the standard AML treatment regimens.

The study compares the investigational product CPX-351 vs the standard treatment for AML in this patients age group.",YES,Acute Myeloid Leukemia,DRUG: CPX-351|DRUG: Cytarabine|DRUG: Daunorubicin,"Number of Participants With Complete Remission, Response was defined according to International Working Group Criteria (Cheson, et al. 2003) which requires peripheral blood neutrophils of \>1000/µL and peripheral blood platelets of \>100,000/µL in the absence of bone marrow blasts., Within 6 weeks of the last induction treatment","Remission Duration/Time to Remission, Remission Duration was assessed from the time measurement criteria for CR were met until the first date that disease relapse was objectively documented or the subject died.

Time to remission was measured from the date of randomization to the time measurement criteria for CR were first met., Following achievement of CR over the study period|Event Free Survival, Event-free survival begins from randomization to the date persistent disease is documented or date of relapse after CR, or death, whichever comes first., Up to 1 year from randomization|Overall Survival Rate at 1 Year, Survival defined as the time from randomization to death., 1 year|Rate of Stem Cell Transplant, The rate of patients who underwent stem cell transplant., Up to 1 year|Aplasia Rate, Bone marrow aplasia was defined as \<20% cellularity and 5% blasts in the bone marrow aspiration evaluation., Day 14 (1st Induction)",,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,126,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CLTR0308-204,2008-10,2010-06,2011-12,2008-11-11,2018-01-12,2018-01-12,"Arizona Cancer Center, Tucson, Arizona, 85724-5024, United States|Cedars Sinai Medical Center, Los Angeles, California, 90048, United States|UC Davis Cancer Center, Sacramento, California, 95817, United States|University of California Medical Center, San Francisco, California, 94143, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Shands Jacksonville Medical Center, Jacksonville, Florida, 32209, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, United States|Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, 30342, United States|Robert H.Lurie Comprehensive Cancer Center, Chicago, Illinois, 60611, United States|Rush University Medical Center, Chicago, Illinois, 60612-3861, United States|St.Francis Hospital, Beech Grove, Indiana, 46107, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Northern New Jersey Cancer Associates, Hackensack, New Jersey, 07601, United States|North Shore University Hospital, Manhasset, New York, 11020, United States|Weil Cornell Medical Center, New York, New York, 10021, United States|New York Medical College, Division of Oncology, Valhalla, New York, 10595, United States|Blumenthal Cancer Center/Mecklenburg Medical Group, Charlotte, North Carolina, 28204, United States|Jewish Hospital, Cincinnati, Ohio, 45236, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|University of Pittsburg Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Joe Arrington Cancer Center, Lubbock, Texas, 79410, United States|Texas Tech University Health Sciences Center, Lubbock, Texas, 79415, United States|Cancer Therapy and Research Center at the University of Texas, San Antonio, Texas, 78229, United States|Froedlert Hospital/Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|BC Cancer Research Center, Vancouver, British Columbia, V5Z 1L3, Canada|Queen Elisabeth II Health Sciences Center, Halifax, Nova Scotia, B3H 2Y9, Canada|McGill University Department of Oncology, Montreal, Quebec, H2W 1S6, Canada",
